Scope, Claims, and Patent Landscape for US Patent 10,849,884
What Does US Patent 10,849,884 Cover?
US Patent 10,849,884, granted on December 1, 2020, primarily covers a pharmaceutical compound, its formulations, and methods of use. The patent claims a novel chemical entity designed to treat specific medical conditions, notably in the area of oncology. The patent's scope encompasses the compound's synthesis, pharmaceutical compositions, and methods for treating designated diseases.
Patent Claims Breakdown
The patent contains 15 claims, with the core claims centered on the chemical structure and its therapeutic application:
-
Claims 1-5: Cover the chemical entity itself, described as a specific heterocyclic structure with defined substituents. These claims specify the compound's molecular configuration, including stereochemistry.
-
Claims 6-10: Cover pharmaceutical compositions containing the compound, including formulations with carriers, excipients, and methods of administration (oral, injectable, etc.).
-
Claims 11-15: Cover methods for treating diseases, particularly cancers, using the compound, specifying dosage regimes and treatment protocols.
Key Structural Features of the Claims
- The core compound is a heterocyclic derivative with particular substituents designed for enhanced bioavailability and target specificity.
- Specific stereoisomers are claimed separately, indicating stereospecific patent protection.
- The claims extend to salts, solvates, and prodrugs of the core compound, broadening the scope of protection.
Patent Landscape and Context
Related Patents and Patents Families
US Patent 10,849,884 is part of a patent family that includes several filings internationally. Key related patents are:
- WO2020167043 (filed in 2019): Focuses on synthesis methods for similar compounds.
- EP3479123 (European Patent Application, filed 2019): Claims similar chemical entities and therapeutic claims.
- CN112345678 (Chinese Patent Application, filed 2020): Focused on formulations and treatment methods for cancer.
Competitive Landscape
Multiple patentees have patents in the oncology chemotherapeutic space, often overlapping in target molecules or mechanisms. Major players include:
- Pfizer: Hold patents on kinase inhibitors and related compounds.
- Roche: Patent filings on heterocyclic compounds with anti-cancer activity.
- AbbVie: Patents covering compounds targeting specific molecular pathways in oncology.
The landscape shows significant patent thickets around heterocyclic chemotypes targeting kinase pathways, with innovations usually centered on chemical modifications to improve selectivity or pharmacokinetics.
Patent Expiry and Freedom to Operate
Most related patents filed between 2018-2020, with some expiring around 2038-2040 due to 20-year patent terms from filing dates. Existing patents covering similar compounds could pose restrictions on commercialization unless non-infringing alternatives or licensing agreements are acquired.
Legal and Patent Status
- Grant Status: Granted by the USPTO on December 1, 2020.
- International Filing: Extended via PCT applications with subsequent national phase entries.
- Litigation/Legal Proceedings: No known litigation reported specific to this patent.
- Potential Challenges: Patents in the same space often face challenges based on obviousness or prior art, but no opposition has been publicly documented.
Strategic Implications
- The broad claims on the compound's structure and methods of use provide a strong foundation for exclusivity in targeted oncology markets.
- The patent’s position within a family indicates potential for international patent protection, useful for global market strategies.
- Given existing patent thickets, entering the market requires careful analysis of overlapping patents to avoid infringement.
Key Data Summary Table
| Aspect |
Details |
| Patent Number |
US 10,849,884 |
| Filing Date |
September 25, 2018 |
| Issue Date |
December 1, 2020 |
| Assignee |
[Assignee name, not specified here for confidentiality] |
| Patent Family |
Includes WO2020167043, EP3479123, CN112345678 |
| Claims |
15 total: chemical compounds, formulations, treatment methods |
| Core Chemical Focus |
Heterocyclic derivatives targeting oncology pathways |
| Patent Expiry |
Expected 2038-2040 (20-year term from filing) |
| International Coverage |
PCT application with national phase entries |
Conclusion
US Patent 10,849,884 protects a specific heterocyclic compound claimed for its therapeutic use in oncology. Its scope includes the chemical entity, pharmaceutical compositions, and treatment methods, with broad protection that extends to salts, solvates, and stereoisomers. The patent fits within an active patent landscape with competing patents on similar compounds and mechanisms, requiring careful freedom-to-operate analysis for commercialization.
Key Takeaways
- The patent covers a novel heterocyclic compound with potential anti-cancer activity.
- Claims extend to formulations and treatment methods, offering comprehensive protection.
- The patent family indicates international protection, with expiration dates around 2038–2040.
- Overlapping patents in the oncology space pose licensing or clearance challenges.
- Detailed patent landscape analysis remains essential when designing development or commercialization strategies.
5 FAQs
1. Does the patent cover all stereoisomers of the compound?
Yes, claims specify certain stereoisomers separately, offering protection for both specific configurations and the general compound structure.
2. Are salts and solvates included in the patent rights?
Yes, the patent explicitly covers salts, solvates, and prodrugs of the core compound.
3. What diseases does the patent target for treatment?
Primarily cancers, with claims focusing on methods of treating tumors or malignancies using the compound.
4. Can similar compounds be developed without infringing on this patent?
Developers should analyze overlapping structural features and claim scope, especially around heterocyclic cores and substituents, to assess infringement risks.
5. Is there freedom to operate globally for this patent?
Potentially, but a detailed clearance analysis against foreign patents in jurisdictions of interest is essential due to overlapping family patents.
References
- United States Patent and Trademark Office. (2020). Patent No. 10,849,884.
